{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T15:21:06Z","timestamp":1712157666179},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,2]]},"DOI":"10.7759\/cureus.21850","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T02:39:51Z","timestamp":1643855991000},"source":"Crossref","is-referenced-by-count":1,"title":["IgG4-Related Disease Presenting as Hypertrophic Pachymeningitis"],"prefix":"10.7759","author":[{"given":"Binita","family":"Sapkota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritesh","family":"Rampure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Gokden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruthi","family":"Kanuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s41016-021-00233-5","article-title":"The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases","volume":"7","author":"Woo PY","year":"2021","unstructured":"Woo PY, Ng BC, Wong JH, Ng OK, Chan TS, Kwok NF, Chan KY. The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases. Chin Neurosurg J. 2021, 7:13. 10.1186\/s41016-021-00233-5","journal-title":"Chin Neurosurg J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino CA","year":"2020","unstructured":"Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020, 16:702-14. 10.1038\/s41584-020-0500-7","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.243","article-title":"IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment","volume":"71","author":"Lu LX","year":"2014","unstructured":"Lu LX, Della-Torre E, Stone JH, Clark SW. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. JAMA Neurol. 2014, 71:785-93. 10.1001\/jamaneurol.2014.243","journal-title":"JAMA Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0508-6","article-title":"A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details","volume":"22","author":"Umehara H","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, et al.. A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. Mod Rheumatol. 2012, 22:1-14. 10.3109\/s10165-011-0508-6","journal-title":"Mod Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/580814","article-title":"Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease","volume":"2012","author":"Masaki Y","year":"2012","unstructured":"Masaki Y, Kurose N, Yamamoto M, et al.. Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease. Int J Rheumatol. 2012, 2012:580814. 10.1155\/2012\/580814","journal-title":"Int J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000568","article-title":"Immunoglobulin G4-related hypertrophic pachymeningitis: a case-oriented review","volume":"6","author":"Levraut M","year":"2019","unstructured":"Levraut M, Cohen M, Bresch S, et al.. Immunoglobulin G4-related hypertrophic pachymeningitis: a case-oriented review. Neurol Neuroimmunol Neuroinflamm. 2019, 6:e568. 10.1212\/NXI.0000000000000568","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-017-0450-9","article-title":"Neurological manifestations of IgG4-related disease","volume":"19","author":"Baptista B","year":"2017","unstructured":"Baptista B, Casian A, Gunawardena H, D'Cruz D, Rice CM. Neurological manifestations of IgG4-related disease. Curr Treat Options Neurol. 2017, 19:14. 10.1007\/s11940-017-0450-9","journal-title":"Curr Treat Options Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.06.024","article-title":"Hypertrophic pachymeningitis","volume":"367","author":"Hahn LD","year":"2016","unstructured":"Hahn LD, Fulbright R, Baehring JM. Hypertrophic pachymeningitis. J Neurol Sci. 2016, 367:278-83. 10.1016\/j.jns.2016.06.024","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.10.008","article-title":"Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis","volume":"266","author":"Della-Torre E","year":"2014","unstructured":"Della-Torre E, Galli L, Franciotta D, et al.. Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis. J Neuroimmunol. 2014, 266:82-6. 10.1016\/j.jneuroim.2013.10.008","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.172908","article-title":"Standard steroid treatment for autoimmune pancreatitis","volume":"58","author":"Kamisawa T","year":"2009","unstructured":"Kamisawa T, Shimosegawa T, Okazaki K, et al.. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009, 58:1504-7. 10.1136\/gut.2008.172908","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers MN","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, et al.. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015, 74:1171-7. 10.1136\/annrheumdis-2014-206605","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo M","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, et al.. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017, 12:e0183844. 10.1371\/journal.pone.0183844","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/79028-igg4-related-disease-presenting-as-hypertrophic-pachymeningitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:53Z","timestamp":1707507893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/79028-igg4-related-disease-presenting-as-hypertrophic-pachymeningitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.21850","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}